crohn's glp 1 Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential GLP-1 Use in Crohn's Disease:

Since initiation, her hemoglobin A1c decreased from 8.6% to 5.6%, insulin therapy was discontinued, and she achieved significant weight loss, with improved liver function and laboratory parameters

Policymakers, insurers, and employers must weigh the benefits of expanding access to these effective medications against the potentiallyunsustainable coststhey introduce.

Missing a single semaglutide injection won't derail your weight loss progress, but timing matters for appetite control and metabolic stability

Trister also talked about plans for the Study Watch and offered views on the Alzheimers research landscape and AI development and regulation in a new era of uncertainty.

Rapid weight loss from GLP-1 medications can cause noticeable facial sagging and hollowing